Biotech

All Articles

Zephyrm looks for Hong Kong IPO to finance period 3 cell treatment trials

.Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, submission (PDF) for an IPO to b...

Frazier Lifestyle Sciences gets $630M for small, mid-cap biotechs

.Frazier Everyday life Sciences has sourced an even further $630 thousand for its fund focused on ti...

GigaGen gathers up to $135M BARDA bucks to beat botulism

.Antibody connoisseur GigaGen, a subsidiary of Spanish biopharma Grifols, is actually ramping up its...

GPCR firm Septerna files for IPO on stamina of preclinical data

.Septerna will learn just how a biotech without "any type of purposeful scientific records" fares in...

Kurma shuts to begin with $154M loot for largest biotech fund as yet

.European VC company Kurma Partners has revealed its own newest biotech fund, with 140 million europ...

Prothena promotes one exec while yet another leaves-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our roundup of considerable leadership hirings, shooting...

Editas capitalize Vertex Cas9 licensing civil liberties for $57M

.Against the background of a Cas9 patent war that refuses to pass away, Editas Medication is moneyin...

Ultragenyx adjusts gene therapy dosing to call up efficiency

.A minority of individuals taking Ultragenyx Pharmaceutical's Wilson ailment gene therapy UX701 have...

Biopharma discharge price maintains in Q3: Brutal Biotech study

.As summer season heat turns to cool winds, hopes that this year will carry widespread market allevi...

J &amp J goes down phase 2 dengue applicant in most current switch from vaccines

.Johnson &amp Johnson's deprioritization of its own transmittable disease pipe has stated another ta...